The company has a market cap of $191.6 million.
ThinkEquity (A division of Fordham Financial Management) and H.C. Wainwright & Co. acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
Alzheon provided the following description of their company for its IPO: ” We are a clinical stage biopharmaceutical company with a late-stage program in Alzheimer’s disease and a discovery platform of small molecules for the inhibition of protein misfolding and aggregation in neurodegenerative disorders. Protein misfolding is an abnormal process in which a protein fails to fold in its normal configuration, rendering the protein toxic or inactive. Our goal is to develop disease modifying treatments for patients with Alzheimer’s and other neurological disorders by leveraging our expertise in inhibiting protein misfolding and aggregation. “.
Alzheon was founded in 2013 and has 6 employees. The company is located at 111 Speen Street, Suite 306, Framingham, MA 01701, US and can be reached via phone at (508) 861-7709 or on the web at http://www.alzheon.com.
Receive News & Ratings for Alzheon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzheon and related companies with MarketBeat.com's FREE daily email newsletter.